ChanRx to evaluate atrial fibrillation candidate with closed Series A funding
This article was originally published in Scrip
Executive Summary
ChanRx Corp, a company based in Cleveland, Ohio that is a spinoff of parent company ChanTest, has closed a Series A round of investment that it will use to further evaluate its investigational candidate for atrial fibrillation, intravenous vanoxerine – a repurposed drug candidate. The firm is focused on small molecules to treat atrial fibrillation.